文献速递药物相互作用治疗药物监测与药物基因组学

长效肌注卡博特韦与利匹韦林的药代动力学及药物相互作用

Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.
PubMed 文献 · Clin Pharmacokinet · 2021-04-08

综述总结长效肌注卡博特韦与利匹韦林的药代动力学及药物相互作用特征。肌注后消除半衰期显著延长,卡博特韦为5.6-11.5周,利匹韦林为13-28周。两药引起DDI潜力低,但可作为DDI受害者,主要经UGT1A1和CYP3A4代谢。

要点

  • 肌注卡博特韦半衰期为5.6-11.5周,利匹韦林为13-28周
  • 卡博特韦主要经UGT1A1代谢,利匹韦林主要经CYP3A4代谢
  • 肌注可消除胃肠道DDI,但肝水平相互作用仍存在

核心结论

  • 肌注卡博特韦与利匹韦林半衰期显著长于口服,DDI潜力低但可作为受害者。

研究设计与样本

  • 综述总结长效肌注卡博特韦与利匹韦林的药理学及DDI特征。

主要发现

  • 肌注卡博特韦消除半衰期为5.6-11.5周,口服为41小时。
  • 肌注利匹韦林消除半衰期为13-28周,口服为45小时。
  • 卡博特韦主要经UGT1A1代谢,利匹韦林主要经CYP3A4代谢。
  • 肌注可消除胃肠道DDI,但肝水平相互作用仍可发生。

关键数值与推荐

  • 卡博特韦肌注消除半衰期5.6-11.5周,口服41小时。
  • 利匹韦林肌注消除半衰期13-28周,口服45小时。

临床怎么用

  • 关注CYP3A4或UGT1A1抑制剂及诱导剂与两药的DDI风险。
  • 肌注给药时需注意肝水平DDI仍可能发生。

局限性

  • 本文为综述,未报告原始研究样本量或效应量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Combined antiretroviral treatments have significantly improved the morbidity and mortality related to HIV infection, thus transforming HIV infection into a chronic disease; however, the efficacy of antiretroviral treatments is highly dependent on the ability of infected individuals to adhere to life-long drug combination therapies. A major milestone in HIV treatment is the marketing of the long-acting intramuscular antiretroviral drugs cabotegravir and rilpivirine, allowing for infrequent drug administration, with the potential to improve adherence to therapy and treatment satisfaction. Intramuscular administration of cabotegravir and rilpivirine leads to differences in pharmacokinetics and drug-drug interaction (DDI) profiles compared with oral administration. A notable difference is the long elimination half-life with intramuscular administration, which reaches 5.6-11.5 weeks for cabotegravir and 13-28 weeks for rilpivirine, compared with 41 and 45 h, respectively, with their oral administration. Cabotegravir and rilpivirine have a low potential to cause DDIs, however these drugs can be victims of DDIs. Cabotegravir is mainly metabolized by UGT1A1, and rilpivirine is mainly metabolized by CYP3A4, therefore these agents are susceptible to DDIs with inhibitors, and particularly inducers of drug-metabolizing enzymes. Intramuscular administration of cabotegravir and rilpivirine has the advantage of eliminating DDIs occurring at the gastrointestinal level, however interactions can still occur at the hepatic level. This review provides insight on the intramuscular administration of drugs and summarizes the pharmacology of long-acting cabotegravir and rilpivirine. Particular emphasis is placed on DDI profiles after oral and intramuscular administration of these antiretroviral drugs.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Hodge D, Back DJ, Gibbons S, et al. Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. Clin Pharmacokinet. 2021. PMID: 33830459. doi:10.1007/s40262-021-01005-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。